296 related articles for article (PubMed ID: 24858062)
1. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Marin F; Gálvez J; Valdés M; Vicente V; Lip GYH
Am J Med; 2014 Nov; 127(11):1083-1088. PubMed ID: 24858062
[TBL] [Abstract][Full Text] [Related]
2. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study.
Roldán V; Cancio S; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Am J Med; 2015 Nov; 128(11):1237-43. PubMed ID: 26087049
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
[TBL] [Abstract][Full Text] [Related]
4. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
[TBL] [Abstract][Full Text] [Related]
5. Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials.
Proietti M; Lane DA; Lip GY
Int J Cardiol; 2016 Aug; 216():168-72. PubMed ID: 27156060
[TBL] [Abstract][Full Text] [Related]
6. SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events.
Pivatto Junior F; Scheffel RS; Ries L; Wolkind RR; Marobin R; Barkan SS; Amon LC; Biolo A
Arq Bras Cardiol; 2017 Apr; 108(4):290-296. PubMed ID: 28538758
[TBL] [Abstract][Full Text] [Related]
7. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
8. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists.
Ruiz-Ortiz M; Bertomeu V; Cequier Á; Marín F; Anguita M
Thromb Haemost; 2015 Oct; 114(4):695-701. PubMed ID: 26054407
[TBL] [Abstract][Full Text] [Related]
9. Use of the SAMe-TT
Zulkifly H; Lip GYH; Lane DA
Heart Rhythm; 2018 Apr; 15(4):615-623. PubMed ID: 29180122
[TBL] [Abstract][Full Text] [Related]
10. The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation.
Esteve-Pastor MA; Roldán V; Valdés M; Lip GY; Marín F
Expert Rev Cardiovasc Ther; 2016; 14(2):177-87. PubMed ID: 26559964
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
[TBL] [Abstract][Full Text] [Related]
12. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldán-Rabadán I; Roldán V; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
Europace; 2018 Sep; 20(9):1435-1441. PubMed ID: 29095971
[TBL] [Abstract][Full Text] [Related]
13. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries.
Cotté FE; Benhaddi H; Duprat-Lomon I; Doble A; Marchant N; Letierce A; Huguet M
Clin Ther; 2014 Sep; 36(9):1160-8. PubMed ID: 25151574
[TBL] [Abstract][Full Text] [Related]
14. CHA2DS2-VASc and SAMe-TT2R2 scores as predictors of recurrence for nonvalvular atrial fibrillation patients on vitamin K antagonists after radiofrequency catheter ablation.
Zhao J; Zhou D; Chen M; Zhuo C; Lin Z; Zheng L; Wang Q
J Cardiovasc Med (Hagerstown); 2020 Mar; 21(3):200-208. PubMed ID: 31977539
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea.
Szymanski FM; Lip GY; Filipiak KJ; Platek AE; Karpinski G
Int J Cardiol; 2016 Feb; 204():200-5. PubMed ID: 26670173
[TBL] [Abstract][Full Text] [Related]
16. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin.
Poli D; Antonucci E; Testa S; Lip GY
Intern Emerg Med; 2014 Jun; 9(4):443-7. PubMed ID: 24652166
[TBL] [Abstract][Full Text] [Related]
17. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
Banerjee A; Clementy N; Haguenoer K; Fauchier L; Lip GY
Am J Med; 2014 Oct; 127(10):972-8. PubMed ID: 24929021
[TBL] [Abstract][Full Text] [Related]
18. Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: AMADEUS Trial.
Senoo K; Lip GY
Stroke; 2015 Nov; 46(11):3202-7. PubMed ID: 26463692
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain.
Lobos-Bejarano JM; Barrios V; Polo-García J; Escobar C; Vargas-Ortega D; Marín-Montañés N; Prieto-Valiente L; Fuentes S; Prieto MA; García-Ortiz L;
Curr Med Res Opin; 2016 Jul; 32(7):1201-7. PubMed ID: 26967541
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
